THERAPY WITH GLP-1 AGONISTS AND DIPEPTIDYL-PEPTIDASE IV INHIBITORS IN TYPE 2 DIABETES MELLITUS
Journal Title: Romanian Journal of Diabetes Nutrition and Metabolic Diseases - Year 2011, Vol 18, Issue 4
Abstract
Since type 2 diabetes is increasing and most patients do not reach their therapeutic goals, novel treatment options are needed. The novel therapeutic options for type 2 diabetes mellitus (Type 2 DM); respectively those based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were introduced in practice in 2005. Incretin therapies consist in two classes: the injectable GLP-1 receptor agonists only acting on the GLP-1 receptor and dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) as oral medications which increase endogenous GLP-1 and other hormone levels by inhibiting their degradation. In Type 2 DM therapy, incretin-based therapies are attractive and frequently used due to their action and safety profile. Insulin secretion stimulation and glucagon secretion inhibition by the above-mentioned drugs occur in a glucose-dependent manner. However, incretinbased therapies have no risk for hypoglycemias. This review gives data of the mechanism of action of these substances and clinical information.
Authors and Affiliations
Nikos Rigas, Floriana Elvira Ionica, Florica Popescu
Keywords
Related Articles
- EP ID EP140105
- DOI -
- Views 98
- Downloads 0
CARDIOVASCULAR RISK CALCULATED ON A GROUP OF PATIENTS WITH TYPE 1 DM DIAGNOSED AT LEAST 10 YEARS AGO
Diabetic nephropathy is the most common worldwide cause of renal chronic disease in terminal stage requiring a renal substitution therapy. Microalbuminuria is an independent risk factor for developing diabetic renal dise...
SLEEVE GASTRECTOMY TO CORRECT OBESITY AND ASSOCIATED CO-MORBIDITIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Obesity has become a serious health problem and it is a major risk factor for the development of insulin resistance and type 2 diabetes mellitus (T2DM). Laparoscopic sleeve gastrectomy (LSG) has revealed to be effective...
HEPATIC FIBROSIS, MEASURED BY FIBROSCANIN A GROUP OF PATIENTS WITH OBESITY
Introduction. Hepatic steatosis is a reversible condition caused by accumulation of triglycerides in liver cells. Non-alcoholic fatty liver disease (NAFLD) can progress to advanced liver disease: fibrosis, cirrhosi...
SLEEP APNEA AND TYPE 2 DIABETES: A SHORT REVIEW OF THE LITERATURE
The prevalence of diabetes and obesity has reached epidemic proportions. Even if today it is an accepted fact that diet and reduced physical activity are causes of obesity epidemic, sleep disturbances are seen as r...
METABOLIC SYNDROME IN PATIENTS WITH T1DM OLDER THAN 10 YEARS
Metabolic Syndrome (MS) is a clinical entity recently individualized, a clinical concept with multiple definitions that expresses a complex disorder of the body′s energy metabolism, with insulin resistance and compensato...